India Globalization Capital Inc Stock News

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports Second Quarter Fiscal 2024 Results.

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy.

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate.

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico.

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC 's 6 Posters on Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms of Dementia at 2023 Alzheimer's Association International Conference.

POTOMAC, MD / ACCESSWIRE / April 18, 2023 / IGC Pharma, Inc. (NYSE American:IGC) today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023, at

POTOMAC, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the “Company”) today announced that Ram Mukunda, Chief Executive Officer, will b

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will co

The House of Representatives intends to vote on a bill to federally legalize cannabis for the second time in history next week, congressional leadership confirmed. The House will take up the Marijua

A wheat-related exchange traded fund surged on Thursday, with wheat futures hitting a 14-year high as Russia's invasion of Ukraine hindered exports from a major global bread basket. Among the best-per

India Globalization Capital, Inc. (AMEX:IGC) announced its financial results for the three months ending December 31, 2021 quarter three of the companys 2022 fiscal year. Q3 Financial Highlights The companys financial results for the quarter ending December 31, 2021 relative to the same period a year ago : The Life Sciences segment , which includes the sale of hemp-based products such as lotion, gummies, and hand sanitizers was the largest revenue driver with $134,000 in revenue for the quarter, compared to $56,000 the year prior. The Infrastructure segment , which includes a construction contract, was $8,000 in the quarter, relative to $52,000 the year prior. The following expense results refer to the quarters ending December 31, 2021, and December 31, 2020: research and development (R&D) expenses related to the Phase 1 clinical trial described above and product research in our Life Sciences segment was approximately $377,000 compared to $154,000 the year prior . We Full story available on Benzinga.

India Globalization Capital, Inc. IGC announced its financial results for the three months ending December 31, 2021 – quarter three of the company's 2022 fiscal year. Q3 Financial Highlights

India Globalization Capital Inc. (IGC) shares closed 0.4% lower than its previous 52 week low, giving the company a market cap of $51M. The stock is currently up 2.3% year-to-date, down 44.8% over the past 12 months, and up 257.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 48.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 74.5% The company's stock price performance over the past 12 months lags the peer average by -364.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

India Globalization Capital Inc. (IGC) shares closed 4.7% lower than its previous 52 week low, giving the company a market cap of $54M. The stock is currently down 32.1% year-to-date, down 39.1% over the past 12 months, and up 253.3% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 40.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -193.0% The company's stock price performance over the past 12 months lags the peer average by -225.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

India Globalization Capital, Inc. (NYSE: IGC) announced Tuesday that it had received positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-base